Cirrus Therapeutics Announces Strategic Expansion To Singapore And Other Key Updates Supporting Its Growth As A Leading Global Ocular Immunology Company

CAMBRIDGE, Mass. and SINGAPORE, March 4 (Bernama) -- Cirrus Therapeutics today announced several business and pipeline updates to support its growth as a leading global ocular immunology company advancing first-in-class and best-in-class therapies to extend the ocular healthspan of patients with chronic blinding diseases.

• Expands to Singapore and appoints Singapore site head. Complementing its UK science origins and US infrastructure, Cirrus has now established an R&D site in Singapore, further expanding its global footprint and gaining access to Asia-Pacific, one of the world’s fastest-growing biopharma markets. Si Hui Tan, PhD has been appointed as Director, Pipeline and Site Head, Singapore. Dr. Tan most recently led the first-in-class liver regeneration program at Lerna Biopharma, a multi-site biotech where she was also a founding member. Dr. Tan holds a PhD in Cancer Biology from Stanford University.